Sumengxiang

(1)Key technologies of illicit drugs control；

(2) Quality controltechnologies for new drugs

1、Educational Experience

1998.9-2002.6  B.S. Pharmaceutical Analysis, China Pharmaceutical University

2004.9-2007.6  M.D. Clinical Pharmacy, China Pharmaceutical University

2009.9-2012.6  Ph.D. Pharmaceutical Analysis, China Pharmaceutical University

2019.11-2020.12  Visiting Scholar, Institute of Human Virology, University of Maryland, Baltimore.

2、Working Experience

2012.7-2016.6 Lecture, Department of Pharmaceutical Analysis, China Pharmaceutical University

2016.7-2022.6 Associate Professor, Department of Pharmaceutical Analysis, China Pharmaceutical University

2022.7-now Professor, Department of Pharmaceutical Analysis, China Pharmaceutical University;

1、Yuqing Yang, Dongping Liu, Zhendong Hua, Peng Xu, Youmei Wang, Bin Di, Jun Liao*, Mengxiang Su*. Machine Learning-Assisted Rapid Screening of Four Types of New Psychoactive Substances in Drug Seizures. Journal of Chemical Information and Modeling. 2023,63(3):815-825. (IF=6.162)

2、Peipei Liu, Wenjuan Liu, Hongwei Qiao, Shan Jiang, Youmei Wang, Jie Chen*, Mengxiang Su*, Bin Di, Simultaneous quantification of 106 drugs or their metabolites in nail samples by UPLC-MS/MS with high-throughput sample preparation: Application to 294 real cases, Analytica Chimica Acta,2022,1226:340170. (IF=6.911)

3、Liping Dong, Wenjuan Liu, Xiaoyuan Zhao, Feng Yu*, Yungen Xu*, Mengxiang Su*. Preclinical Drug Pharmacokinetic, Tissue Distribution and Excretion Profiles of the Novel Limonin Derivate HY-071085 as an Anti-inflammatory and Analgesic Candidate in Rats and Beagle Dogs. Pharmaceuticals. 2022. 15(7): 801. (IF=5.215)

4、Shuo Yang, Yan Shi, Zhuonan Chen, Mobing Chen, Xinze Liu, Wei Liu*, Mengxiang Su*, Bin Di. Detection of mescaline in human hair samples by UPLC-MS/MS: application to 19 authentic forensic cases. Journal of Chromatography B. 2022,1195:123202. (IF=3.318)

5、Qingqing Xiao, Xiaotong Li, Chang Liu, Yi Yang, Yuqi Hou, Ying Wang, Mengxiang Su*, Wei He*. Liposome-based anchoring and core-encapsulation f-orcombinatorial cancer therapy. Chinese Chemical Letters,2022,4191-4196.(IF=8.455)

6、Shan Jiang, Yuling Zhong, Hongwei Qiao, Bin Di, Jie Chen*, Mengxiang Su*. UPLC-MS/MS method for the simultaneous quantification of caffeine and illicit psychoactive drugs in hair using a single-step high-speed grinding extraction – Insights into a cut-off value for caffeine abuse, Journal of Pharmaceutical and Biomedical Analysis, 2022,209,114489. (IF=3.571)

7、Lancheng Wang, Huimin Zhou, Kun Yan, Peng Xu, Bin Di, Chi Hu?, Mengxiang Su*. Using dual exonucleases to finely distinguish structural adjustment of aptamers for small-molecule detection. RSC Advances, 2021, 11, 32898 – 32903. (IF=4.036)

8、Zuoling Zhang, Min Xia, Pengfei Huang, Bin Di, Mengxiang Su*. Preparation and evaluation of a bacitracin-bonded silica stationary phase for hydrophilic interaction liquid chromatography. Microchemical Journal,2021;170:106661.(IF=5.304)

9、Yuxin Zhao, Bo Wu, Zhendong Hua, Peng Xu, Hui Xu, Wenbin Shen, Bin Di, Youmei Wang*, Mengxiang Su*. Quantification of Mexedrone and its Analogues Using 1H‐quantitative NMR without Reference Standard. Analytical Sciences. 2021,37(11):1577-1582. (IF=1.967)

(1)10/2022-09/2025  PI: 45%( sub-project), active grants, Research on Targeted and Non Targeted Laboratory Detection Technology for Synthetic Cannabinoid Drugs 

The National Key Research and Development Program of China (2022YFC3300902)

(2)01/2019-12/2022  PI: 100%, completed grants,“Novel methods on rapid early warning screening and structural identification of new psychoactive substances in complex matrix”. The Natural Science Foundation of China (81872833)

(3)07/2018-06/2021  PI: 21% ( sub-project), completed grants, “Research of technologies for drug use estimation based on environmental sample analysis”, The National Key Research and Development Program of China (2018YFC0807402)

(4)01/2015-12/2017  PI: 100%, completed grants,“Study on chiral separation mechanism of new nature cyclopeptide bonded core-shell silica spheres chiral stationary phases for separation of pharmaceutical enantiomers”.The Natural Science Foundation of China(81402900)

(5)07/2013-06/2016  PI: 100%, completed grants, “Construction of a high-throughput drug candidates screening model based on the immobilization of aromatase on novel hybrid mesoporous silica sphere”. The Natural Science Foundation of Jiangsu Province(BK20130654)